Decreased activity adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: less active than usual

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 10,547 adverse event reports that record the MedDRA preferred term Decreased activity. In plain words, the term means: less active than usual. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 613 reports in the 12 months to June 2026 and 711 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 870 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 613 (under 0.1%) record this term. Reports for patients 75 and over were 11.2% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

Less active than usual. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 118 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Decreased activity name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	50
Acetaminophen		25
Adempas	Soluble guanylate cyclase stimulator	57
Advair Hfa	Corticosteroid	37
Albuterol	beta2-Adrenergic agonist	38
Albuterol sulfate	beta2-Adrenergic agonist	77
Alvesco		76
Ambrisentan	Endothelin receptor antagonist	69
Asacol		39
Aspirin	Nonsteroidal anti-inflammatory drug	50
Atorvastatin		37
Atripla		144
Avandia		53
Avonex	Interferon beta	44
Azathioprine	Purine antimetabolite	30
Bactrim	Dihydrofolate reductase inhibitor antibacterial	42
Breo Ellipta	Corticosteroid	32
Cabometyx	Kinase inhibitor	30
Calquence	Kinase inhibitor	28
Carbidopa levodopa	Aromatic amino acid	25
Carvedilol	alpha-Adrenergic blocker	27
Celebrex	Nonsteroidal anti-inflammatory drug	33
Chantix	Partial cholinergic nicotinic agonist	37
Cialis	Phosphodiesterase 5 inhibitor	55
Clonazepam	Benzodiazepine	31
Complera	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	41
Cosentyx	Interleukin-17A antagonist	66
Crestor	HMG-CoA reductase inhibitor	29
Cymbalta		85
Digoxin	Cardiac glycoside	37
Duodopa		28
Dupixent	Interleukin-4 receptor alpha antagonist	261
Eliquis	Factor Xa inhibitor	35
Enbrel	Tumor necrosis factor blocker	103
Entresto	Angiotensin 2 receptor blocker	567
Escitalopram	Serotonin reuptake inhibitor	30
Euthyrox		28
Farxiga	Sodium-Glucose cotransporter 2 inhibitor	31
Fasenra	Interleukin-5 receptor alpha-directed cytolytic antibody	42
Felodipine	Dihydropyridine calcium channel blocker	34
Forteo	Parathyroid hormone analog	200
Gabapentin	Anti-epileptic agent	49
Gilenya	Sphingosine 1-phosphate receptor modulator	36
Humira		148
Ibuprofen	Nonsteroidal anti-inflammatory drug	34
Imbruvica	Kinase inhibitor	53
Infliximab	Tumor necrosis factor blocker	50
Ipratropium bromide	Anticholinergic	43
Jakafi	Janus kinase inhibitor	565
Keytruda	Programmed death Receptor-1 blocking antibody	53
Latuda	Atypical antipsychotic	88
Lenvima	Kinase inhibitor	48
Levaquin		29
Lipitor	HMG-CoA reductase inhibitor	44
Lisinopril	Angiotensin converting enzyme inhibitor	28
Lyrica		61
Mepolizumab	Interleukin-5 antagonist	64
Metformin	Biguanide	85
Methotrexate	Folate analog metabolic inhibitor	92
Metoprolol	beta-Adrenergic blocker	44
Mounjaro	GLP-1 receptor agonist	31
Niraparib	Poly(ADP-Ribose) polymerase inhibitor	458
Novothyrox		106
Nucala	Interleukin-5 antagonist	53
Ofev	Kinase inhibitor	49
Olanzapine	Atypical antipsychotic	28
Omalizumab	Anti-IgE	66
Opsumit	Endothelin receptor antagonist	80
Orenitram	Prostacycline vasodilator	57
Orgovyx	Gonadotropin releasing hormone receptor antagonist	59
OxyContin	Opioid agonist	29
Prednisone	Corticosteroid	198
Pregabalin		34
Premarin	Estrogen	28
Prolia	RANK ligand inhibitor	92
Prozac	Serotonin reuptake inhibitor	38
Quetiapine	Atypical antipsychotic	41
Quinapril hydrochloride	Angiotensin converting enzyme inhibitor	27
Qvar		42
Remicade	Tumor necrosis factor blocker	49
Remodulin	Prostacycline vasodilator	61
Revlimid	Thalidomide analog	55
Risperdal	Atypical antipsychotic	28
Risperidone	Atypical antipsychotic	42
Rituxan	CD20-directed cytolytic antibody	35
Rituximab	CD20-directed cytolytic antibody	52
Salbutamol		33
Salbutamol sulfate		53
Seroquel	Atypical antipsychotic	33
Singulair	Leukotriene receptor antagonist	39
Stivarga	Kinase inhibitor	42
Stribild	Cytochrome P450 3A inhibitor	57
Symbicort	Corticosteroid	138
Synthroid	l-Thyroxine	51
Tecfidera		50
Terbutaline sulfate		36
Tiotropium bromide	Anticholinergic	130
Toviaz		34
Tracleer	Endothelin receptor antagonist	31
Treprostinil	Prostacycline vasodilator	39
Truvada	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	179
Tysabri	Integrin receptor antagonist	46
Tyvaso	Prostacycline vasodilator	66
Tyvaso DPI	Prostacycline vasodilator	54
Uptravi	Prostacyclin receptor agonist	55
Valsartan	Angiotensin 2 receptor blocker	45
Venclexta	BCL-2 inhibitor	70
Viread	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	108
Xeljanz	Janus kinase inhibitor	63
Xolair	Anti-IgE	88
Xtandi	Androgen receptor inhibitor	35
Zejula	Poly(ADP-Ribose) polymerase inhibitor	129
Zelboraf	Kinase inhibitor	34
Zenhale		67
Zepbound	GLP-1 receptor agonist	25
Zithromax	Macrolide antimicrobial	25
Zolpidem	gamma-Aminobutyric acid A receptor positive modulator	31
Zyprexa	Atypical antipsychotic	27

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 46 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Decreased activity name, in order of name
Class	Reports with this term
Angiotensin 2 receptor blocker	658
Angiotensin converting enzyme inhibitor	74
Anti-epileptic agent	124
Anti-IgE	154
Anticholinergic	209
Atypical antipsychotic	458
BCL-2 inhibitor	70
Benzodiazepine	91
beta-Adrenergic blocker	65
beta2-Adrenergic agonist	122
Biguanide	94
CD20-directed cytolytic antibody	108
Corticosteroid	614
Cytochrome P450 3A inhibitor	57
Endothelin receptor antagonist	206
Factor Xa inhibitor	59
Folate analog metabolic inhibitor	115
GLP-1 receptor agonist	83
Gonadotropin releasing hormone receptor antagonist	59
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	112
HMG-CoA reductase inhibitor	94
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	220
Interferon beta	57
Interleukin-17A antagonist	70
Interleukin-4 receptor alpha antagonist	266
Interleukin-5 antagonist	117
Interleukin-5 receptor alpha-directed cytolytic antibody	57
Janus kinase inhibitor	641
Kinase inhibitor	517
l-Thyroxine	56
Leukotriene receptor antagonist	79
Mood stabilizer	52
Nonsteroidal anti-inflammatory drug	165
Opioid agonist	148
Parathyroid hormone analog	200
Phosphodiesterase 5 inhibitor	92
Poly(ADP-Ribose) polymerase inhibitor	618
Programmed death Receptor-1 blocking antibody	86
Prostacyclin receptor agonist	59
Prostacycline vasodilator	314
RANK ligand inhibitor	96
Serotonin and norepinephrine reuptake inhibitor	53
Serotonin reuptake inhibitor	216
Soluble guanylate cyclase stimulator	60
Thalidomide analog	79
Tumor necrosis factor blocker	258

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Decreased activity, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Decreased activity
Age	Reports	Share
Under 2	117	1.1%
2 to 11	187	1.8%
12 to 17	99	0.9%
18 to 44	1,183	11.2%
45 to 64	2,249	21.3%
65 to 74	1,299	12.3%
75 and over	1,179	11.2%
Age not given	4,234	40.1%

Sex of the patient in the reports that record Decreased activity
Sex	Reports	Share
Female	5,479	51.9%
Male	3,642	34.5%
Unknown or not given	1,426	13.5%

Age and sex are as the report gives them. 72.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Decreased activity: adverse event reports that record this term. https://reportedreactions.com/reaction/decreased-activity/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Decreased activity mean in an adverse event report?

In plain words: less active than usual. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page